Therapeutic in vivo synthetic chemistry using an artificial metalloenzyme with glycosylated human serum albumin

Adv Carbohydr Chem Biochem. 2022:82:11-34. doi: 10.1016/bs.accb.2022.10.001. Epub 2022 Nov 10.

Abstract

The concept of "therapeutic in vivo synthetic chemistry" refers to chemical synthesis in living systems using new-to-nature reactions for the treatment or diagnosis of diseases. This review summarizes our development of therapeutic in vivo synthetic chemistry using glycan-modified human serum albumin (glycoHSA) and utilizing the selective glycan-targeting and metal protective effects of metal catalysts. The four artificial metalloenzymes with glycoHSA provided good cancer treatment results based on on-site drug synthesis and selective cell-tagging strategies. Thus, we propose that therapeutic in vivo synthetic chemistry using glycoHSA as a new modality of therapy or diagnosis is applicable to a wide range of diseases.

Keywords: Artificial metalloenzymes; Cancer therapy; Cell targeting; Glycan-modified human serum albumin; Therapeutic in vivo synthetic chemistry.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Catalysis
  • Humans
  • Metalloproteins*
  • Metals
  • Serum Albumin, Human

Substances

  • Metalloproteins
  • Metals
  • Serum Albumin, Human